Cited 30 times in
Effects of pregnane X receptor (NR1I2) and CYP2B6 genetic polymorphisms on the induction of bupropion hydroxylation by rifampin.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 정재용 | - |
dc.date.accessioned | 2014-12-20T16:23:03Z | - |
dc.date.available | 2014-12-20T16:23:03Z | - |
dc.date.issued | 2011 | - |
dc.identifier.issn | 0090-9556 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/92613 | - |
dc.description.abstract | We investigated genetic polymorphisms in the pregnane X receptor (NR1I2) in Korean individuals (n = 83) and the effects of NR1I2 genotypes on rifampin-mediated induction of bupropion hydroxylation. The pharmacokinetics of bupropion and hydroxybupropion were evaluated after an oral dose of bupropion (150 mg) administered before and after rifampin treatment for 7 days in 35 healthy subjects. The area under the time-concentration curve (AUC) ratio of hydroxybupropion to bupropion in CYP2B6*6 carriers was significantly lower than that in CYP2B6*6 noncarriers in both the basal and rifampin-induced states (p = 0.012). Among the CYP2B6*6 carriers (n = 13), the NR1I2 TGT (-25385T + g.7635G + g.8055T) carriers exhibited a significantly lower AUC ratio, representing the CYP2B6 hydroxylation activity, compared with the TGT noncarriers, in the induced state (11.9 versus 20.3, p = 0.045). The percent difference in the AUC ratio between the basal and induced states was also significantly different (212% versus 58.8%, p = 0.006). However, no significant difference was observed among the NR1I2 TGT genotypes for the CYP2B6*6 noncarriers (n = 22). In conclusion, it is suggested the NR1I2 TGT genotype decreases the bupropion hydroxylation induced by treatment with rifampin, particularly in CYP2B6*6 carriers. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 92~97 | - |
dc.relation.isPartOf | DRUG METABOLISM AND DISPOSITION | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Aryl Hydrocarbon Hydroxylases/genetics* | - |
dc.subject.MESH | Aryl Hydrocarbon Hydroxylases/metabolism | - |
dc.subject.MESH | Asian Continental Ancestry Group/genetics | - |
dc.subject.MESH | Bupropion/analogs & derivatives* | - |
dc.subject.MESH | Bupropion/blood | - |
dc.subject.MESH | Bupropion/metabolism* | - |
dc.subject.MESH | Cytochrome P-450 CYP2B6 | - |
dc.subject.MESH | Drug Interactions | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Genotype | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Hydroxylation | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Oxidoreductases, N-Demethylating/genetics* | - |
dc.subject.MESH | Oxidoreductases, N-Demethylating/metabolism | - |
dc.subject.MESH | Polymorphism, Single Nucleotide* | - |
dc.subject.MESH | Receptors, Steroid/genetics* | - |
dc.subject.MESH | Receptors, Steroid/metabolism | - |
dc.subject.MESH | Rifampin/pharmacology* | - |
dc.title | Effects of pregnane X receptor (NR1I2) and CYP2B6 genetic polymorphisms on the induction of bupropion hydroxylation by rifampin. | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Pharmacology (약리학) | - |
dc.contributor.googleauthor | Jae Yong Chung | - |
dc.contributor.googleauthor | Joo-Youn Cho | - |
dc.contributor.googleauthor | Hyeong-Seok Lim | - |
dc.contributor.googleauthor | Jung-Ryul Kim | - |
dc.contributor.googleauthor | Kyung-Sang Yu | - |
dc.contributor.googleauthor | Kyoung Soo Lim | - |
dc.contributor.googleauthor | Sang-Goo Shin | - |
dc.contributor.googleauthor | In-Jin Jang | - |
dc.identifier.doi | 10.1124/dmd.110.035246 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A03709 | - |
dc.relation.journalcode | J00749 | - |
dc.identifier.eissn | 1521-009X | - |
dc.identifier.pmid | 20876786 | - |
dc.contributor.alternativeName | Chung, Jae Yong | - |
dc.contributor.affiliatedAuthor | Chung, Jae Yong | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 39 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 92 | - |
dc.citation.endPage | 97 | - |
dc.identifier.bibliographicCitation | DRUG METABOLISM AND DISPOSITION, Vol.39(1) : 92-97, 2011 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.